An announcement by DelMar Pharmaceuticals regarding its purchase of 760,500 shares of common stock

cancer therapies

A biopharma firm which focuses on the development & commercialization of novel cancer therapies, DelMar Pharmaceuticals Inc., made an announcement today about the closing of its formerly announced registered direct offering of 1,170k shares of common stock and, in a parallel private placement, warrants to buy 760,500 shares of common stock at a joint purchase price of $3.10 per share and related warrant. The warrants have a term of exercise of 5 years.

Dawson James Securities Inc. acted as a co-placement agent whereas Maxim Group LLC acted as the lead placement agent in connection with the transaction.

The shares of the common stock were offered access to an effective shelf registration statement on Form S-3, as edited, which was previously filed with the Securities and Exchange Commission & declared effective on 27th of September three years back. A final prospectus supplement & accompanying prospectus which is related to the terms of the offering has been filed with the Securities and Exchange Commission and are available on the website of the Securities and Exchange Commission. Copies of the accompanying prospectus and the final prospectus supplement may be obtained by contacting Maxim Group LLC, at their location in Lexington Avenue, New York or by means of an email or telephone.

An offer to sell shall not be constituted by this press release or the solicitation of an offer to purchase, nor there may be any sale of these securities in any jurisdiction or state in which such a solicitation, offer, or sale would be illegal prior to qualification or registration under the securities laws of any such jurisdiction or state.

About DelMar Pharmaceuticals

The leadership team at DelMar Pharmaceuticals is committed to contributing to the battle against cancer by researching and developing new cancer therapies which would treat the patients with the significant unmet clinical need.